Catalysta Ventures, LLC 4
4 · PhaseBio Pharmaceuticals Inc · Filed Oct 24, 2018
Insider Transaction Report
Form 4
Hatteras Venture Advisors III, LLC
10% Owner
Transactions
- Conversion
Common Stock
2018-10-22+52,690→ 52,690 total(indirect: By Hatteras Venture Partners I, LP) - Conversion
Common Stock
2018-10-22+266,481→ 266,481 total(indirect: By Venture Capital Multiplier Fund) - Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−19,061→ 0 total(indirect: By Hatteras Venture Partners III, LP)Exercise: $0.12→ Series B Preferred Stock (19,061 underlying) - Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+19,061$2,287→ 1,045,222 total(indirect: By Hatteras Venture Partners III, LP)→ Common Stock (19,061 underlying) - Exercise of In-Money
Series B Preferred Stock
2018-10-22$0.12/sh+1,731$208→ 94,916 total(indirect: By Hatteras Venture Affiliates III, LP)→ Common Stock (1,731 underlying) - Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−47,458→ 0 total(indirect: By Hatteras Venture Partners III, LP)Exercise: $0.12→ Series C-1 Preferred Stock (47,458 underlying) - Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−1,139$5,695→ 149,320 total(indirect: By Hatteras Venture Partners III, LP)→ Common Stock (1,139 underlying) - Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+4,309$517→ 13,662 total(indirect: By Hatteras Venture Affiliates III, LP)→ Common Stock (4,309 underlying) - Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−41,414→ 0 total(indirect: By Venture Capital Multiplier Fund)Exercise: $0.12→ Series C-1 Preferred Stock (41,414 underlying) - Purchase
Common Stock
2018-10-22$5.00/sh+137,513$687,565→ 1,820,933 total(indirect: By Hatteras Venture Partners III, LP) - Purchase
Common Stock
2018-10-22$5.00/sh+150,000$750,000→ 416,481 total(indirect: By Venture Capital Multiplier Fund) - Conversion
Common Stock
2018-10-22+1,683,420→ 1,683,420 total(indirect: By Hatteras Venture Partners III, LP) - Conversion
Common Stock
2018-10-22+150,612→ 150,612 total(indirect: By Hatteras Venture Affiliates III, LP) - Purchase
Common Stock
2018-10-22$5.00/sh+12,487$62,435→ 163,099 total(indirect: By Hatteras Venture Affiliates III, LP) - Sale
Series B Preferred Stock
2018-10-22$5.00/sh−458$2,290→ 1,044,764 total(indirect: By Hatteras Venture Partners III, LP)→ Common Stock (458 underlying) - Conversion
Series 1 Preferred Stock
2018-10-22−42,530→ 0 total(indirect: By Hatteras Venture Partners III, LP)→ Common Stock (42,530 underlying) - Conversion
Series 1 Preferred Stock
2018-10-22−4,846→ 0 total(indirect: By LLC)→ Common Stock (4,846 underlying) - Conversion
Series C-1 Preferred Stock
2018-10-22−149,320→ 0 total(indirect: By Hatteras Venture Partners III, LP)→ Common Stock (149,320 underlying) - Conversion
Series C-1 Preferred Stock
2018-10-22−13,558→ 0 total(indirect: By Hatteras Venture Affiliates III, LP)→ Common Stock (13,558 underlying) - Conversion
Common Stock
2018-10-22+4,846→ 4,846 total(indirect: By LLC) - Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−104$520→ 13,558 total(indirect: By Hatteras Venture Affiliates III, LP)→ Common Stock (104 underlying) - Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+41,414$4,970→ 41,414 total(indirect: By Venture Capital Multiplier Fund)→ Common Stock (41,414 underlying) - Conversion
Series 1 Preferred Stock
2018-10-22−3,862→ 0 total(indirect: By Hatteras Venture Affiliates III, LP)→ Common Stock (3,862 underlying) - Conversion
Series C-1 Preferred Stock
2018-10-22−40,420→ 0 total(indirect: By Venture Capital Multiplier Fund)→ Common Stock (40,420 underlying) - Conversion
Series D Preferred Stock
2018-10-22−272,107→ 0 total(indirect: By Hatteras Venture Partners III, LP)→ Common Stock (272,107 underlying) - Exercise of In-Money
Warrants to Purchase Series B Preferred Stock
2018-10-22−1,731→ 0 total(indirect: By Hatteras Venture Affiliates III, LP)Exercise: $0.12→ Series B Preferred Stock (1,731 underlying) - Sale
Series B Preferred Stock
2018-10-22$5.00/sh−42$210→ 94,874 total(indirect: By Hatteras Venture Affiliates III, LP)→ Common Stock (42 underlying) - Conversion
Series D Preferred Stock
2018-10-22−24,709→ 0 total(indirect: By Hatteras Venture Affiliates III, LP)→ Common Stock (24,709 underlying) - Exercise of In-Money
Series C-1 Preferred Stock
2018-10-22$0.12/sh+47,458$5,695→ 150,459 total(indirect: By Hatteras Venture Partners III, LP)→ Common Stock (47,458 underlying) - Exercise of In-Money
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−4,309→ 0 total(indirect: By Hatteras Venture Affiliates III, LP)Exercise: $0.12→ Series C-1 Preferred Stock (4,309 underlying) - Sale
Series C-1 Preferred Stock
2018-10-22$5.00/sh−994$4,970→ 40,420 total(indirect: By Venture Capital Multiplier Fund)→ Common Stock (994 underlying) - Conversion
Series B Preferred Stock
2018-10-22−1,044,764→ 0 total(indirect: By Hatteras Venture Partners III, LP)→ Common Stock (1,044,764 underlying) - Conversion
Series B Preferred Stock
2018-10-22−94,874→ 0 total(indirect: By Hatteras Venture Affiliates III, LP)→ Common Stock (94,874 underlying) - Conversion
Series D Preferred Stock
2018-10-22−226,061→ 0 total(indirect: By Venture Capital Multiplier Fund)→ Common Stock (226,061 underlying) - Conversion
Series 1 Preferred Stock
2018-10-22−52,690→ 0 total(indirect: By Hatteras Venture Partners I, LP)→ Common Stock (52,690 underlying) - Conversion
Series AA Preferred Stock
2018-10-22−174,699→ 0 total(indirect: By Hatteras Venture Partners III, LP)→ Common Stock (174,699 underlying) - Conversion
Series AA Preferred Stock
2018-10-22−13,609→ 0 total(indirect: By Hatteras Venture Affiliates III, LP)→ Common Stock (13,609 underlying)
Footnotes (5)
- [F1]Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
- [F2]Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
- [F3]HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
- [F4]Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
- [F5]The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.